Glucose Transporters in Brain: In Health and in Alzheimer’s Disease
The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Abstract
Neurons need a continuous supply of glucose, the major source of energy for mammalian brain metabolism. The central nervous system is protected by three main physiological cell barriers. Cell membranes are impermeable for glucose, therefore glucose is transferred across the cell membranes by specific transport proteins: sodium-independent glucose transporters (GLUTs), encoded by SLC2 genes, and sodium-dependent glucose transporters (for example SGLTs), encoded by SLC5 genes. Human brain expresses 10 GLUT proteins and 10 proteins encoded by SLC5 genes. In patients with brain diseases, particularly Alzheimer's (AD) and Huntington's diseases, abnormalities in neuronal glucose metabolism have been showed. The levels of GLUT1 and GLUT3, the major brain glucose transporters, are decreased, especially in the cerebral cortex. Therefore, in AD, hypometabolism of glucose and deficits in energy are observed. Production of ATP from glucose metabolism in sporadic AD declines to 50% and the tendency to decline continues throughout the progression of the disease. This decrease is correlated with O-GlcAcetylation and tau hyperphosphorylation, as the compensatory mechanisms in AD are the utilization of endogenous brain substances and drastic increase in GLUT2 levels. The present review focuses on the changes in the expression of glucose transporters due to AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“researchers asserted that besides its role in glucose reabsorption, SGLT may exhibit other distinct functions in CNS.13–15”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [13]
Citations
Cites
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“Therefore, the concept of AD was proposed as “type 3 diabetes” [124].”
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Translating cell biology into therapeutic advances in Alzheimer's disease
Selkoe, D. J. (1999) · Nature · doi:10.1038/399a023 · Cited by 1,166 · cited 1×
“A (cid:2) 40 and A (cid:2) 42 are generated by the proteolytic cleavage of A (cid:2) PP with (cid:2) - and (cid:4) -secretases [132].”
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
Insulin receptors are widely distributed in the central nervous system of the rat
HAVRANKOVA, J., ROTH, J., & BROWNSTEIN, M. (1978) · Nature · doi:10.1038/272827a0 · Cited by 1,111
De Vivo, D. C., Trifiletti, R. R., Jacobson, R. I., Ronen, G. M., Behmand, R. A., & Harik, S. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251006 · Cited by 800
Research works printed but not linked: 2
- Welcome, 2011, Long-term disorders of cognitive functions in sober people who episodically use alcohol, role of functional hypoglycemia and insufficiency of gluconeogenesis, Vestnik Smolensk Med Acad, 3, 2
- Welcome, 2013, State of cognitive functions of student-medics with different relationship to alcohol use, 5
Cited by
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
“Inefficient glucose utilization, impaired ATP production, and oxidative damage are closely correlated, and these deficiencies have profound consequences in AD.(387,388) For example, ATP deficiency causes the loss of the neuronal membrane potential since Na/K ATPase fails to maintain proper intracellular and extracellu…”
BackgroundVallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
“Hypometabolism of glucose and deficits in energy are observed in AD [107].”
BackgroundGlucose metabolic crosstalk and regulation in brain function and diseases
Zhang, S., Lachance, B. B., Mattson, M. P., & Jia, X. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102089 · Cited by 203
The solute carrier transporters and the brain: Physiological and pharmacological implications
Hu, C., Tao, L., Cao, X., & Chen, L. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.09.002 · Cited by 157
“SLCs function in energy metabolism he energy demands of the brain are very high and glucose s the obligatory energy substrate of the adult brain [57 ,58] . lucose is a polar, hydrophilic molecule that is transported argely via the glucose transporter SLC2A [59] .”
BackgroundInfluentialA Systematic Review of Glucose Transport Alterations in Alzheimer's Disease
Kyrtata, N., Emsley, H. C. A., Sparasci, O., Parkes, L. M., & Dickie, B. R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.626636 · Cited by 171
“…mainly present in non-cerebral fat and muscle tissue, GLUT8, which has been suggested to contribute toward glucose homeostasis in hippocampal neurons (Piroli et al., 2002), and GLUT12, a newly discovered glucose transporter found primarily in insulin-sensitive tissues (Szablewski, 2017).”
BackgroundEnergy Metabolism Decline in the Aging Brain—Pathogenesis of Neurodegenerative Disorders
Błaszczyk, J. W. (2020) · Metabolites · doi:10.3390/metabo10110450 · Cited by 162
“GLUT-3 activity is critical in protecting against hypoglycemia [28,49,63].”
BackgroundInsulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
Berlanga-Acosta, J., Guillén-Nieto, G., Rodríguez-Rodríguez, N., Bringas-Vega, M. L., García-del-Barco-Herrera, D., Berlanga-Saez, J. O., García-Ojalvo, A., Valdés-Sosa, M. J., & Valdés-Sosa, P. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.560375 · Cited by 136
“Hyperinsulinemia, regardless of stimulating peripheral lactate production, hampers its neuronal availability and utilization by limiting its flux across the BBB (214).”
BackgroundInfluentialEndothelial cell barriers: Transport of molecules between blood and tissues
Yazdani, S., Jaldín‐Fincati, J. R., Pereira, R. V. S., & Klip, A. (2019) · Traffic · doi:10.1111/tra.12645 · Cited by 137
“GLUT1/ SLC2A1 is the primary transporter of the BBB and glial cells, whereas neurons express GLUT3 and small numbers of some glucose-sensing neurons also express GLUT2 and/or GLUT4.(17) The neuronal expression of GLUT3 (which has higher affinity to glucose than GLUT1, 2 and 4) was probably selected during evolution to…”
BackgroundHan, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
“The hypometabolism of glucose and deficits in ATP production is observed in AD [33,34].”
BackgroundVerma, A., Shteinfer‐Kuzmine, A., Kamenetsky, N., Pittala, S., Paul, A., Crystal, E. N., Ouro, A., Caspi, V. C., Pandey, S. K., Monsonego, A., et al. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00329-7 · Cited by 116
“Therefore, it is not surprising that metabolic dysregulation contributes to the progression of AD [8, 10, 36, 109].”
InfluentialNguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97
Huttunen, J., Peltokangas, S., Gynther, M., Natunen, T., Hiltunen, M., Auriola, S., Ruponen, M., Vellonen, K.-S., & Huttunen, K. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-49009-z · Cited by 96
Austad, S. N., Ballinger, S. W., Buford, T. W., Carter, C. S., Smith, D. L., Darley-Usmar, V. M., & Zhang, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.06.014 · Cited by 100
Glucose transporter 3 in neuronal glucose metabolism: Health and diseases
Peng, W., Tan, C., Mo, L., Jiang, J., Zhou, W., Du, J., Zhou, X., Liu, X., & Chen, L. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154869 · Cited by 278
Duarte, A. I., Candeias, E., Alves, I. N., Mena, D., Silva, D. F., Machado, N. J., Campos, E. J., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051746 · Cited by 90
“Another feature of AD is the impairment in brain glucose transport and metabolism [46,47].”
BackgroundIn vivo methods for imaging blood–brain barrier function and dysfunction
Harris, W. J., Asselin, M., Hinz, R., Parkes, L. M., Allan, S. M., Schießl, I., Boutin, H., & Dickie, B. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05997-1 · Cited by 98
Glucose metabolism, neural cell senescence and Alzheimer's disease
Wang, Q., Duan, L., Li, X., Wang, Y., Guo, W., Guan, F., & Ma, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084351 · Cited by 90
“GLUT1 and GLUT3 are also significantly reduced in the brains of AD patients [100,101].”
BackgroundSzablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158142 · Cited by 84
“Importantly, GLUT1 is not expressed in neurons [6,15,16].”
BackgroundSelf-citationBehnoush, A. H., Mousavi, A., Ghondaghsaz, E., Shojaei, S., Cannavò, A., & Khalaji, A. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105582 · Cited by 87
Vulnerability of the Hippocampus to Insults: Links to Blood–Brain Barrier Dysfunction
Davidson, T. L., & Stevenson, R. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25041991 · Cited by 90
“Glucose is the main fuel source for mammalian brains [236], and it depends on the glucose transporter GLUT1 to cross the BBB from the bloodstream into the extracellular space [237,238], whereas another transporter, GLUT3, facilitates glucose uptake by neurons [239].”
BackgroundDysfunction of the Blood-Brain Barrier—A Key Step in Neurodegeneration and Dementia
Noe, C. R., Noe-Letschnig, M., Handschuh, P., Noe, C. A., & Lanzenberger, R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00185 · Cited by 73
“This finding is crucial for and consistent with increasingly upcoming hypotheses, relating dementia to metabolic dysfunction or energy deficits of the brain (Jurcovicova, 2014; Szablewski, 2017).”
ResultRole of Hypoxia Inducible Factor-1α in Alzheimer’s Disease
Wang, Y., Huang, Z., Yuan, M., Feng, J., Cai, R.-L., Zou, Q., Pu, Y., Wang, S., Chen, F., Yi, W., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201448 · Cited by 81
“In Liu’s study [64], reduced HIF-1 (cid:2) level is correlated with downregulation of GLUT-1 and GLUT-3, which impaired glucose metabolism [65].”
Dysregulation of energy metabolism in Alzheimer's disease
Yuan, Y., Zhao, G., & Zhao, Y. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12800-8 · Cited by 254
El-Sahar, A. E., Rastanawi, A. A., El-Yamany, M. F., & Saad, M. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118076 · Cited by 70
Metabolic Control of Epilepsy: A Promising Therapeutic Target for Epilepsy
Fei, Y., Shi, R., Song, Z. Q., & Wu, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.592514 · Cited by 70
Brain glucose and ketone utilization in brain aging and neurodegenerative diseases
Kapogiannis, D., & Avgerinos, K. I. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.015 · Cited by 70
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
Cacabelos, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093059 · Cited by 66
“SNPs in genes encoding transporter proteins may affect brain penetrance and accessibility to neuronal/glial targets, drug metabolism, and drug resistance [70,74,75].”
BackgroundMetabolic and Cellular Compartments of Acetyl-CoA in the Healthy and Diseased Brain
Jankowska-Kulawy, A., Klimaszewska‐Łata, J., Gul‐Hinc, S., Ronowska, A., & Szutowicz, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710073 · Cited by 75
Zhao, Z., Yan, J., Huang, L., & Yang, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116373 · Cited by 61
Distribution of glucose transporters in renal diseases
Szablewski, L. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0371-7 · Cited by 65
Self-citationStorelli, F., Billington, S., Kumar, A. R., & Unadkat, J. D. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 57
Imamura, T., Yanagihara, Y. T., Ohyagi, Y., Nakamura, N., Iinuma, K. M., Yamasaki, R., Asai, H., Maeda, M., Murakami, K., Irie, K., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104739 · Cited by 53
“37 GLUT1 and 3 are expressed in neurons whereas GLUT2 is expressed in astrocytes (Szablewski, 2017).”
Targeting organ-specific mitochondrial dysfunction to improve biological aging
Madreiter‐Sokolowski, C. T., Hiden, U., Krstić, J., Panzitt, K., Wagner, M., Enzinger, C., Khalil, M., Abdellatif, M., Malle, E., Madl, T., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108710 · Cited by 59
The role of neurovascular unit damage in the occurrence and development of Alzheimer’s disease
Liu, X., Hou, D., Lin, F., Luo, J., Xie, J., Wang, Y., & Tian, Y. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0056 · Cited by 60
Exercise, Arterial Stiffness, and Cerebral Vascular Function: Potential Impact on Brain Health
Barnes, J. N., Pearson, A. G., Corkery, A. T., Eisenmann, N. A., & Miller, K. B. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721000394 · Cited by 55
“In the human brain, Alzheimer’s disease is associated with reduced glucose transporters in the blood–brain barrier (Kalaria & Harik, 1989; Szablewski, 2017).”
BackgroundVallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8486-x · Cited by 54
Alzheimer’s Disease: A Molecular View of β-Amyloid Induced Morbific Events
Asik, R. M., Suganthy, N., Aarifa, M. A., Kumar, A., Szigeti, K., Máthé, D., Gulyás, B. Z., Archunan, G., & Padmanabhan, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091126 · Cited by 56
Chen, Y., Joo, J. D., Chu, J. M. T., Chang, R. C., & Wong, G. T. C. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02905-8 · Cited by 54
“Less-glycosylated GLUT1 with the molecular mass of 45 kDa is expressed on the end-feet of astrocytes that surrounded by capillaries [21, 24].”
BackgroundYonamine, C. Y., Michalani, M. L. E., Moreira, R. J., & Machado, U. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216480 · Cited by 54
Jia, Y., Wang, N., Zhang, Y., Xue, D., Lou, H., & Liu, X. (2020) · Aging and disease · doi:10.14336/ad.2019.0519 · Cited by 46
“Evidence has shown that glucose transport is reduced in AD patients’ brain regions, such as the cortex, hippocampus, and cerebral microvessels [58].”
BackgroundCacabelos, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1779700 · Cited by 52
Targeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
“Consistent evidence from human studies and animal studies has revealed abnormal glucose metabolism in the brain that could occur prior to AD pathology and cognitive impairment, including reduced GLUT1 and GLUT3 [54,55], impaired insulin signaling [56,57], aberrant glucose metabolism [58–60], mitochondrial dysfunction…”
BackgroundRiluzole: a therapeutic strategy in Alzheimer’s disease by targeting the WNT/β-catenin pathway
Vallée, A., Vallée, J.-N., Guillevin, R., & Lecarpentier, Y. (2020) · Aging · doi:10.18632/aging.102830 · Cited by 52
“Glucose hypo-metabolism and energy deficiency is observed in AD brains [116].”
BackgroundLiu, D., Gao, Q., Wang, Y., & Xiong, T. (2022) · Placenta · doi:10.1016/j.placenta.2022.07.014 · Cited by 49
The Role of Oxygen Homeostasis and the HIF-1 Factor in the Development of Neurodegeneration
Mitroshina, E. V., & Vedunova, M. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094581 · Cited by 48
“Conditional knockout of HIF-1 α in young adult mice led to neuronal alterations and a 40% reduction in TH expression in the substantia nigra [131,132].”
BackgroundYue, Q., Leng, X., Xie, N., Zhang, Z., Yang, D., & Hoi, M. P. M. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70079 · Cited by 48
Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders
Mitra, S., Banik, A., Saurabh, S., Maulik, M., & Khatri, S. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0998-21.2022 · Cited by 50
“While GLUT1 and GLUT3 levels are decreased in the cerebral cortex, the levels of GLUT2 are increased to compensate for the reduction in ATP production (Szablewski, 2016).”
Jasbi, P., Shi, X., Chu, P. S., Elliott, N. M., Hudson, H., Jones, D. C., Serrano, G. E., Chow, B., Beach, T. G., Liu, L., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00290 · Cited by 50
Gupta, S. N., Singh, V., Ganesh, S., Singhal, N. K., & Sandhir, R. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c15305 · Cited by 46
Lower GLUT1 and unchanged MCT1 in Alzheimer’s disease cerebrovasculature
Leclerc, M., Tremblay, C., Bourassa, P., Schneider, J. A., Bennett, D. A., & Calon, F. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241237484 · Cited by 46
Expression of glucose transporters in human neurodegenerative diseases
Głuchowska, K., Pliszka, M., & Szablewski, L. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.12.067 · Cited by 47
Self-citationDoes hyperglycemia downregulate glucose transporters in the brain?
Leão, L. L., Tangen, G. G., Barca, M. L., Engedal, K., Santos, S. H. S., Machado, F. S. M., de Paula, A. M. B., & Monteiro-Júnior, R. S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109614 · Cited by 46
Fehsel, K., & Christl, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101592 · Cited by 47
Han, S., He, Z., Hu, X., Li, X., Zheng, K., Huang, Y., Xiao, P., Xie, Q., Ni, J., & Liu, Q. (2023) · Antioxidants · doi:10.3390/antiox12030722 · Cited by 43
Scholefield, M., Unwin, R. D., & Cooper, G. J. S. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101152 · Cited by 39
He, C., Li, Q., Cui, Y., Gao, P., Shu, W., Zhou, Q., Wang, L., Li, L., Lu, Z., Zhao, Y., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.154595 · Cited by 42
Gao, R., Ku, T., Ji, X., Zhang, Y., Li, G., & Sang, N. (2017) · Journal of Environmental Sciences · doi:10.1016/j.jes.2017.06.037 · Cited by 38
Effects of progesterone on glucose uptake in neurons of Alzheimer's disease animals and cell models
Wu, H., Wu, Z.-G., Shi, W., Gao, H. Y., Wu, H., Bian, F., Jia, P., & Yan-ning, H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116979 · Cited by 39
Liu, X., Li, J., He, D., Zhang, D., & Liu, X. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.084 · Cited by 37
Zakharova, I. O., Соколова, Т. В., Bayunova, L. V., Zorina, I. I., Rychkova, M. P., Shpakov, A. O., & Avrova, N. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153702 · Cited by 36
The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration
Ansari, S. A., & Emerald, B. S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00473 · Cited by 36
“Insulin resistance in the brain is observed due to defects in insulin receptors signaling (Kuljis and Salkovic-Petrisic, 2011) and decreased levels of brain glucose transporters, Glut1 and Glut3 (Liu et al., 2008; Szablewski, 2017) which is also observed in AD brain.”
BackgroundWen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
“describe central distribution and the related function.(18,72) So far, preclinical investigations on the relationships between CNS and SGLT-2i are scarce, possibly because energy regula-”
BackgroundAhmad, R. M. A. H., Ababneh, N. A., & Al-Domi, H. A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102468 · Cited by 39
Bridging the gap: glucose transporters, Alzheimer’s, and future therapeutic prospects
Albaik, M., Saleh, D. S., Kauther, D., Mohammed, H., Alfarra, S., Alghamdi, A., Ghaboura, N., & Sindi, I. A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1344039 · Cited by 36
“…1 (SGLT1) agonists, Dipeptidyl peptidase IV (DPP4) inhibitors, Glucagon-like peptide-1 receptor (GLP-1 RAs) agonists, liposomes, insulin, and Small interfering RNA (siRNA) have been shown to be effective in treating Alzheimer ’ s disease (Szablewski, 2017; Szablewski, 2021a; Wang et al., 2023).”
InfluentialZuliani, I., Lanzillotta, C., Tramutola, A., Barone, E., Perluigi, M., Rinaldo, S., Paone, A., Cutruzzolà, F., Bellanti, F., Spinelli, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073746 · Cited by 35
Rojas-Pirela, M., Andrade-Alviárez, D., Rojas, V., Marcos, M., Salete-Granado, D., Chacón-Arnaude, M., Pérez-Nieto, M. Á., Kemmerling, U., Concepción, J. L., Michels, P. A. M., et al. (2025) · Open Biology · doi:10.1098/rsob.240239 · Cited by 32
“The loss of these transporters would not only cause ATP production to decline by 50%, with a tendency to decrease with disease progression [261], but also promote the accumulation of amyloid plaques, composed of the amyloid precursor protein (APP) product amyloid beta (Aβ), and the intracellular…”
Backeström, A., Papadopoulos, K. I., Eriksson, S., Olsson, T., Andersson, M., Blennow, K., Zetterberg, H., Nyberg, L. H., & Rolandsson, O. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247753 · Cited by 35
“A key player in upholding neuronal activity in metabolically active brain regions is glucose transporter 3 (GLUT-3) [38].”
BackgroundInfluentialGLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 32
“…as insulin resistance and These include disruptions in glucose transport, such as insulin resistance and anomalous glucose transporter activity [16], as well as alterations in blood flow dynamics [17]. anomalous glucose transporter activity [16], as well as alterations in blood flow dynamics…”
BackgroundThe role of cell type-specific mitochondrial dysfunction in the pathogenesis of Alzheimer's disease
Kim, D., & Mook‐Jung, I. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.12.282 · Cited by 32
“down-regulated in patients with AD (16, 17).”
Lecanemab: More Questions Than Answers!
Kaur, U., Reddy, J., Tiwari, A., Chakrabarti, S., & Chakrabarti, S. S. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01331-1 · Cited by 30
Butterfield, D. A., Favia, M., Spera, I., Campanella, A., Lanza, M., & Castegna, A. (2022) · Molecules · doi:10.3390/molecules27030951 · Cited by 30
“However, the expression of insulin-sensitive GLUT4 in the brain confirms that glucose metabolism in the brain is at least partially regulated by insulin [89].”
BackgroundThe Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome
Zuliani, I., Lanzillotta, C., Tramutola, A., Francioso, A., Pagnotta, S. E., Barone, E., Perluigi, M., & Domenico, F. D. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00978-4 · Cited by 29
Shin, B., Cepeda, C., Estrada‐Sánchez, A. M., Levine, M. S., Hodaei, L., Dai, Y., Jung, J. W., Ganguly, A., Clark, P. M., & Devaskar, S. U. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0503-18.2018 · Cited by 29
“Conversely, a reduction in GLUT3 expression is a hallmark of Alzheimer’s disease (Shah et al., 2012; Szablewski, 2017).”
BackgroundGLUT12 Expression in Brain of Mouse Models of Alzheimer’s Disease
Gil‐Iturbe, E., Solas, M., Cuadrado‐Tejedor, M., García‐Osta, A., Escoté, X., Ramírez, M. J., & Lostao, M. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01743-1 · Cited by 29
Chen, J., Gao, L., Zhang, Y., Su, Y., Kong, Z., Wang, D., & Yan, M. (2020) · Phytotherapy Research · doi:10.1002/ptr.6811 · Cited by 28
“Although Glu T plays a vital role in regulating glucose transport and maintaining energy homeostasis in the brain, insulin-independent Glu T4, Glu T1, and Glu T3 glucose uptake is absent in the brain (Simpson, Chundu, Davies-Hill, Honer, & Davies, 1994; Szablewski, 2016).”
BackgroundGalizzi, G., Palumbo, L., Amato, A., Conigliaro, A., Nuzzo, D., Terzo, S., Caruana, L., Picone, P., Alessandro, R., Mulè, F., et al. (2021) · Mitochondrion · doi:10.1016/j.mito.2021.08.014 · Cited by 28
Roles of traditional chinese medicine regulating neuroendocrinology on AD treatment
Deng, C., Chen, H., Meng, Z., & Meng, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.955618 · Cited by 30
Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis
de Roovaart, H. J. V., Nguyen, N., & Veenstra, T. D. (2023) · Pharmaceuticals · doi:10.3390/ph16111513 · Cited by 28
“Several genes associated with metabolism including glucose transporter 1 (GLUT1), GLUT3, and insulin along with members of the sortilin family [39–41] have been shown to be altered in HD.”
BackgroundCisternas, P., Gherardelli, C., Gutiérrez, J., Salazar, P. L., Méndez‐Orellana, C., Wong, G. W., & Inestrosa, N. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1237796 · Cited by 29
Gu, J., Jin, N., Ma, D., Chu, D., Iqbal, K., Gong, C., & Liu, F. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171047 · Cited by 27
Energetic evolution of cellular Transportomes
Darbani, B., Kell, D. B., & Borodina, I. (2018) · BMC Genomics · doi:10.1186/s12864-018-4816-5 · Cited by 28
“At a molecular level, although both the solute carrier SLC2 family of facilitated glucose transporters and the SLC5 family of energy-dependent sodium/glucose cotransporters participate in glucose uptake, the human brain has largely been dependent on SLC2 transporters for the energetically free supply of glucose [44].”
BackgroundPorel, P., Bala, K., & Aran, K. R. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01585-x · Cited by 28
Liu, P., Chen, T., Tan, F., Tian, J., Zheng, L., Deng, Y., Chen, J., & Chi, X. (2020) · Bioscience Reports · doi:10.1042/bsr20191994 · Cited by 25
Development of a deep-red fluorescent glucose-conjugated bioprobe for in vivo tumor targeting
Cheng, Y., Shabir, G., Li, X., Fang, L., Xu, L., Zhang, H., & Li, E. (2019) · Chemical Communications · doi:10.1039/c9cc07363a · Cited by 25
Essa, H., Peyton, L., Hasan, W., León, B. E., & Choi, D. (2022) · Cells · doi:10.3390/cells11020286 · Cited by 28
“Glucose is the principal substrate for the human adult brain under normal physiological circumstances, and its consumption is extensively utilized as one prime measure to evaluate metabolism of energy in the brain [44].”
BackgroundDoes Diet Have a Role in the Treatment of Alzheimer's Disease?
Thelen, M., & Brown‐Borg, H. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.617071 · Cited by 25
“Additionally, transgenic mutations introduced into mice are not able to match the complexity seen in AD such that no mouse models can reproduce the full spectrum of human AD symptoms and pathology (Tai et al., 2017).”
BackgroundCzeczor, J. K., & McGee, S. L. (2017) · Journal of Neuroendocrinology · doi:10.1111/jne.12470 · Cited by 23
Zhang, X., Wu, L., Swerdlow, R. H., & Zhao, L. (2023) · Cells · doi:10.3390/cells12030410 · Cited by 22
“Glucose transporters exist in several isoforms, including GLUT1–GLUT4, and GLUT1 and GLUT3 are found to be downregulated in AD brains [32].”
SLC2A3 rs12842 polymorphism and risk for Alzheimer’s disease
Arseniou, S., Siokas, V., Aloizou, A., Stamati, P., Mentis, A. A., Tsouris, Z., Dastamani, M., Peristeri, E., Valotassiou, V. J., Bogdanos, D. P., et al. (2020) · Neurological Research · doi:10.1080/01616412.2020.1786973 · Cited by 23
Palix, C., Felisatti, F., Gonneaud, J., Kuhn, E., Mézenge, F., Landeau, B., Chocat, A., Quillard, A., Egret, S., Delarue, M., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.06.004 · Cited by 22
“For instance, changes in glucose transporters function and expression or dysfunction in glycolysis (conversion of glucose to energy) could affect brain glucose homeostasis (Hipkiss, 2019; Szablewski, 2016) and thus affect cerebral metabolism.”
Ginsenoside compound K ameliorates Alzheimer’s disease in HT22 cells by adjusting energy metabolism
Chen, X., Li, H., Yang, Q., Lan, X., Wang, J., Cao, Z., Shi, X., Li, J., Kan, M., Qu, X., et al. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04988-0 · Cited by 22
Xu, L., Huang, H., Zhao, M. F., Zhu, G.-C., & Xu, Z. (2020) · Neurocritical Care · doi:10.1007/s12028-020-01011-4 · Cited by 21
Andrographolide restores glucose uptake in rat hippocampal neurons
Gherardelli, C., Cisternas, P., Gutiérrez, J., Martínez, M., & Inestrosa, N. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15229 · Cited by 21
Therapies for Alzheimer’s disease: a metabolic perspective
Domingues, R., Pereira, C., Cruz, M. T., & Silva, A. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.01.011 · Cited by 25
Stapel, B., Gorinski, N., Gmahl, N., Rhein, M., Preuss, V., Hilfiker‐Kleiner, D., Frieling, H., Bleich, S., Ponimaskin, E. G., & Kahl, K. G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1675639 · Cited by 21
“been described in the context of dementia [9,37], one might speculate that fluoxetine-induced palmitoylation of this glucose transporter, at least in the human system, might contribute to the beneficial effects of fluoxetine treatment in this disease presumably by stabilizing glucose handling.”
BackgroundRosch, J. C., Neal, E. H., Balikov, D. A., Rahim, M., & Lippmann, E. S. (2020) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-020-00651-y · Cited by 20
“in several diseases including Glucose Transporter Type 1 Deficiency Syndrome [18], Alzheimer’s Disease [19], and brain microvasculature defects [20].”
BackgroundVasconcelos-Filho, F. S. L., Oliveira, L. C. D. R., de Freitas, T. B. C., de Pontes, P. A. D. S., da Rocha-e-Silva, R. C., Chaves, E. M. C., da Silva, C. G. L., Soares, P. M., & Ceccatto, V. M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119372 · Cited by 23
Han, X., Ren, H., Nandi, A., Fan, X., & Koehler, R. C. (2021) · Scientific Reports · doi:10.1038/s41598-021-90216-4 · Cited by 24
Metadata
- Authors
- Szablewski, L.
- Affiliations
- Medical University of Warsaw (PL)
- Corresponding author
- Szablewski, Leszek
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-12-20
- Volume
- 55
- Issue
- 4
- Pages
- 1307-1320
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2554650037
- Cited by
- 211
- References
- 161
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 25 · 2023: 20 · 2022: 30 · 2021: 32 · 2020: 35 · 2019: 19 · 2018: 6 · 2017: 6
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- glucose transporters, Alzheimer's disease
- MeSH terms
- Acetylation, Alzheimer Disease, Animals, Brain, Gene Expression Regulation, Humans, Phosphorylation, tau Proteins, N-Acetylglucosaminyltransferases, Glucose Transport Proteins, Facilitative
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.